Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 2Uveal Melanoma 1Polyps 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Colonic Neoplasms 1Colonic Diseases 1

Interventions

pembrolizumab 7Ipilimumab 7Nivolumab 5Melphalan 5Dacarbazine 3tebentafusp 2sotrastaurin 2binimetinib 2Pemetrexed 2Crizotinib 2ADI PEG20 2utomilumab 1trametinib 1tocilizumab 1siremadlin 1ruxolitinib 1relatlimab 1obinutuzumab 1fludarabine phosphate 1fludarabine 1cemiplimab 1avelumab 1Watchful Waiting 1Toll-Like Receptor 1 1Standard of Care 1Solutions 1Rose Bengal 1Protein Kinase C 1Polyethylene Glycols 1Opdualag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uveal Melanoma × Polyethylene Glycols × Clear all
NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Polaris Group

Phase 1 Completed
8 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡